Christopher McCoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher McCoy has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Sangro
Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra, Madrid, Spain
9 shared publications - Clara Aicart-Ramos
Department of Macromolecular Structures, Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain
9 shared publications - Eva M. Martín-Cuevas
Department of Macromolecular Structures, Spanish National Centre for Biotechnology (CNB), Spanish National Research Council (CSIC), Madrid, Spain
9 shared publications - Jessica Zucman-Rossi
Centre de Recherche des Cordeliers 1 Paris, France
9 shared publications - Juan Pablo Unfried
Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel
9 shared publications - Linda Lee
Department of Biochemistry and Molecular Biology, Robson DNA Science Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada
9 shared publications
Latest Publications
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2793. Clinical Outcomes of Combination Therapy with Daptomycin and Ceftaroline for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
IDSA MRSA Treatment Guidelines recommend vancomycin or daptomycin as first-line therapy for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI). Limited data and few recommendations exist regarding combination treatment for MRSA BSI outside of prosthetic valve endocarditis (PVE). The alternative treatment option of combining daptomycin with ceftaroline for its synergistic mechanism possibly through β-lactam-induced reduction in cell wall cross-linking has been pursued. This regimen is less feasible for home administration and more information on when to de-escalate to monotherapy after blood culture clearance is needed. This study evaluated clinical outcomes for patients with MRSA BSI who received combination therapy with daptomycin and ceftaroline. This was a single-center, retrospective study evaluating hospitalized patients mostly with persistent MRSA BSI from 1/2019 to 7/2022 who received a combination of daptomycin and ceftaroline. Patients with a diagnosis of pneumonia, PVE or polymicrobial bacteremia were excluded. The primary endpoint assessed in-hospital mortality for patients on combination therapy. Secondary endpoints included readmission within 90 days, reoccurrence of bacteremia within 30 days, length of stay and adverse drug reactions during treatment. This study demonstrated a variable duration of combination therapy for MRSA BSI in low-risk patients. The in-hospital mortality rate observed was low. All had microbiological cure. However, further exploration is needed to determine the optimal time for de-escalation after blood culture clearance. Future studies could contribute to creating stewardship efforts to de-escalate patients for MRSA BSI. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2793. Clinical Outcomes of Combination Therapy with Daptomycin and Ceftaroline for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
IDSA MRSA Treatment Guidelines recommend vancomycin or daptomycin as first-line therapy for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI). Limited data and few recommendations exist regarding combination treatment for MRSA BSI outside of prosthetic valve endocarditis (PVE). The alternative treatment option of combining daptomycin with ceftaroline for its synergistic mechanism possibly through β-lactam-induced reduction in cell wall cross-linking has been pursued. This regimen is less feasible for home administration and more information on when to de-escalate to monotherapy after blood culture clearance is needed. This study evaluated clinical outcomes for patients with MRSA BSI who received combination therapy with daptomycin and ceftaroline. This was a single-center, retrospective study evaluating hospitalized patients mostly with persistent MRSA BSI from 1/2019 to 7/2022 who received a combination of daptomycin and ceftaroline. Patients with a diagnosis of pneumonia, PVE or polymicrobial bacteremia were excluded. The primary endpoint assessed in-hospital mortality for patients on combination therapy. Secondary endpoints included readmission within 90 days, reoccurrence of bacteremia within 30 days, length of stay and adverse drug reactions during treatment. This study demonstrated a variable duration of combination therapy for MRSA BSI in low-risk patients. The in-hospital mortality rate observed was low. All had microbiological cure. However, further exploration is needed to determine the optimal time for de-escalation after blood culture clearance. Future studies could contribute to creating stewardship efforts to de-escalate patients for MRSA BSI. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
666. Evaluation of Vancomycin Harms for Intra-abdominal Infections
The Infectious Diseases Society of America recommends broad spectrum Gram-negative and anaerobic coverage for complicated intra-abdominal infections (IAI). Gram-positive beta lactam resistant organisms such as methicillin-resistant S. aureus (MRSA) are not typically associated with pathogenicity. Vancomycin, an empiric Gram-positive agent, is associated with nephrotoxicity. This study evaluated incidence of harm in patients treated with antimicrobial regimens which included vancomycin vs. those which did not. This single center, retrospective cohort study included adult inpatients admitted between September 1, 2018 and September 30, 2022 with a diagnosis of IAI. Patients with concomitant MRSA infection from a different site or who received hemodialysis or continuous renal replacement therapy were excluded. The primary outcome was the rate of renal toxicity in patients treated empirically for IAI. Secondary outcomes included duration of treatment, duration of hospitalization, and evaluation of guideline concordant use of vancomycin in IAI. Baseline Characteristics Primary and Secondary Outcomes More patients who were treated with vancomycin experienced acute kidney injury. Patients who were treated with standard therapy were more likely to have a reduced hospital length of stay and shorter inpatient antibiotic duration of treatment. Institutional guidelines recommend no additional coverage outside of specific risk factors but stewardship efforts do not extend to this use. Future efforts to decrease use of vancomycin for IAI may result in a decrease in observed harms. Further studies are needed to refine which patients may truly benefit from empirical vancomycin therapy. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access666. Evaluation of Vancomycin Harms for Intra-abdominal Infections
The Infectious Diseases Society of America recommends broad spectrum Gram-negative and anaerobic coverage for complicated intra-abdominal infections (IAI). Gram-positive beta lactam resistant organisms such as methicillin-resistant S. aureus (MRSA) are not typically associated with pathogenicity. Vancomycin, an empiric Gram-positive agent, is associated with nephrotoxicity. This study evaluated incidence of harm in patients treated with antimicrobial regimens which included vancomycin vs. those which did not. This single center, retrospective cohort study included adult inpatients admitted between September 1, 2018 and September 30, 2022 with a diagnosis of IAI. Patients with concomitant MRSA infection from a different site or who received hemodialysis or continuous renal replacement therapy were excluded. The primary outcome was the rate of renal toxicity in patients treated empirically for IAI. Secondary outcomes included duration of treatment, duration of hospitalization, and evaluation of guideline concordant use of vancomycin in IAI. Baseline Characteristics Primary and Secondary Outcomes More patients who were treated with vancomycin experienced acute kidney injury. Patients who were treated with standard therapy were more likely to have a reduced hospital length of stay and shorter inpatient antibiotic duration of treatment. Institutional guidelines recommend no additional coverage outside of specific risk factors but stewardship efforts do not extend to this use. Future efforts to decrease use of vancomycin for IAI may result in a decrease in observed harms. Further studies are needed to refine which patients may truly benefit from empirical vancomycin therapy. All Authors: No reported disclosures
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Long noncoding RNAs (lncRNA) are emerging as key players in cancer as parts of poorly understood molecular mechanisms. Here, we investigated lncRNAs that play a role in hepatocellular carcinoma (HCC) and identified NIHCOLE, a novel lncRNA induced in HCC with oncogenic potential and a role in the ligation efficiency of DNA double-stranded breaks (DSB). NIHCOLE expression was associated with poor prognosis and survival of HCC patients. Depletion of NIHCOLE from HCC cells led to impaired proliferation and increased apoptosis. NIHCOLE deficiency led to accumulation of DNA damage due to a specific decrease in the activity of the nonhomologous end-joining (NHEJ) pathway of DSB repair. DNA damage induction in NIHCOLE-depleted cells further decreased HCC cell growth. NIHCOLE was associated with DSB markers and recruited several molecules of the Ku70/Ku80 heterodimer. Further, NIHCOLE putative structural domains supported stable multimeric complexes formed by several NHEJ factors including Ku70/80, APLF, XRCC4, and DNA ligase IV. NHEJ reconstitution assays showed that NIHCOLE promoted the ligation efficiency of blunt-ended DSBs. Collectively, these data show that NIHCOLE serves as a scaffold and facilitator of NHEJ machinery and confers an advantage to HCC cells, which could be exploited as a targetable vulnerability.Significance:This study characterizes the role of lncRNA NIHCOLE in DNA repair and cellular fitness in HCC, thus implicating it as a therapeutic target.See related commentary by Barcena-Varela and Lujambio, p. 4899
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Long noncoding RNAs (lncRNA) are emerging as key players in cancer as parts of poorly understood molecular mechanisms. Here, we investigated lncRNAs that play a role in hepatocellular carcinoma (HCC) and identified NIHCOLE, a novel lncRNA induced in HCC with oncogenic potential and a role in the ligation efficiency of DNA double-stranded breaks (DSB). NIHCOLE expression was associated with poor prognosis and survival of HCC patients. Depletion of NIHCOLE from HCC cells led to impaired proliferation and increased apoptosis. NIHCOLE deficiency led to accumulation of DNA damage due to a specific decrease in the activity of the nonhomologous end-joining (NHEJ) pathway of DSB repair. DNA damage induction in NIHCOLE-depleted cells further decreased HCC cell growth. NIHCOLE was associated with DSB markers and recruited several molecules of the Ku70/Ku80 heterodimer. Further, NIHCOLE putative structural domains supported stable multimeric complexes formed by several NHEJ factors including Ku70/80, APLF, XRCC4, and DNA ligase IV. NHEJ reconstitution assays showed that NIHCOLE promoted the ligation efficiency of blunt-ended DSBs. Collectively, these data show that NIHCOLE serves as a scaffold and facilitator of NHEJ machinery and confers an advantage to HCC cells, which could be exploited as a targetable vulnerability.Significance:This study characterizes the role of lncRNA NIHCOLE in DNA repair and cellular fitness in HCC, thus implicating it as a therapeutic target.See related commentary by Barcena-Varela and Lujambio, p. 4899
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Supplementary Materials and Methods
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Supplementary Materials and Methods